Xin Lang Cai Jing·2025-09-08 03:32Core Points - The stock price of Junshi Biosciences dropped by 2.00% on September 8, reaching 47.04 CNY per share, with a total market capitalization of 48.295 billion CNY [1] - Year-to-date, the stock has increased by 72.12%, with a slight decline of 0.15% over the last five trading days, and increases of 10.58% and 31.58% over the last 20 and 60 days, respectively [1] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion CNY, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million CNY, an increase of 36.01% year-on-year [2] Company Overview - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and industrialization of monoclonal antibody drugs and other therapeutic protein drugs [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category, and is involved in the development and technology transfer of monoclonal antibody drugs [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, while the average number of circulating shares per person decreased by 5.56% to 24,543 shares [2] - The top ten circulating shareholders include notable ETFs, with the Huaxia SSE Sci-Tech Innovation Board 50 ETF holding 29.7167 million shares, a decrease of 536,700 shares from the previous period [2]